Buy Abilify (Aripiprazole) Online — Atypical Antipsychotic for Schizophrenia, Bipolar Disorder & Depression

Abilify is the brand name for aripiprazole, a prescription atypical antipsychotic medication approved by the FDA in 2002. It is used to treat several psychiatric conditions including schizophrenia, bipolar disorder, treatment-resistant depression (as an add-on), irritability associated with autism in children, and Tourette syndrome. Abilify is sometimes called a third-generation antipsychotic or dopamine system stabilizer because it works differently from both older typical antipsychotics and earlier atypical drugs like risperidone or olanzapine.

Conditions Abilify treats

Abilify is FDA-approved for the following indications:

• 🧠 Schizophrenia in adults and adolescents (ages 13–17)
• 🎢 Acute manic and mixed episodes of bipolar I disorder — alone or with lithium or valproate
• 🎢 Bipolar I maintenance therapy to prevent recurrence
• 😔 Adjunctive treatment of major depressive disorder — added to an antidepressant when response is incomplete
• 👶 Irritability associated with autism spectrum disorder in children (ages 6–17)
• 🤸 Tourette syndrome in children and adolescents (ages 6–18)
• 🏥 Agitation in adults with schizophrenia or bipolar mania (intramuscular injection)

What Abilify does NOT do

Abilify is not a cure for the psychiatric conditions it treats. It does not eliminate schizophrenia, bipolar disorder, or autism. What it does is reduce symptoms, prevent relapse, and allow patients to function in daily life. Treatment is typically long-term or lifelong for chronic conditions like schizophrenia and bipolar disorder.

Abilify is also not a first-line treatment for anxiety, attention deficit hyperactivity disorder (ADHD), or simple depression. It is not a stimulant, not a sedative, and not addictive. It does not produce euphoria or recreational effects. Abilify is also not approved for behavioural disturbances in elderly patients with dementia — in fact, it carries a boxed warning against this use due to increased mortality risk in that population.

Abilify works through a fundamentally different mechanism than older antipsychotics. Where first-generation drugs simply block dopamine receptors and second-generation atypicals block dopamine and serotonin, aripiprazole acts as a partial agonist — meaning it can both activate and inhibit dopamine signalling depending on what the brain needs. This unique mechanism explains its favourable side-effect profile and is why it is sometimes called a "dopamine system stabilizer".

The 4-step mechanism

Why this matters in practice

The clinical consequences of this triple mechanism explain several important features of Abilify:

• Lower risk of movement disorders — because aripiprazole does not fully block D2 receptors, extrapyramidal side effects (parkinsonism, dystonia, tardive dyskinesia) occur less often than with older antipsychotics
• Less weight gain and metabolic disturbance — compared to olanzapine, clozapine, and quetiapine
• Lower prolactin elevation — because D2 receptors in the pituitary retain some activity
• Akathisia is more common than with some other atypicals — this is the signature aripiprazole side effect
• Once-daily dosing works because of the 75-hour half-life and stable receptor occupancy

The most distinctive feature of Abilify compared to other antipsychotics is its role as a dopamine system stabilizer. This concept — central to understanding why aripiprazole works the way it does — reflects how the drug interacts with the dopamine system in a fundamentally different way than older medications.

The dopamine paradox in psychiatric illness

Psychiatric disorders often involve dysregulation of dopamine, not simply too much or too little of it:

• Schizophrenia (positive symptoms) — hallucinations and delusions are linked to excess dopamine activity in the mesolimbic pathway
• Schizophrenia (negative symptoms) — apathy, social withdrawal, and motivation deficits are linked to insufficient dopamine activity in the prefrontal cortex
• Movement disorders from antipsychotics — tremor, rigidity, and tardive dyskinesia from too little dopamine in the nigrostriatal pathway after full D2 blockade
• Prolactin elevation — insufficient dopamine in the tuberoinfundibular pathway from full D2 blockade

Older antipsychotics treat the excess dopamine in psychosis but worsen the deficits in other pathways. This is why first-generation antipsychotics cause prominent movement disorders, and why even atypicals can cause negative symptoms or prolactin problems.

How partial agonism balances these effects

Comparison with other antipsychotics

What partial agonism does NOT mean

It is a common misunderstanding that aripiprazole "doesn't really work" or "only partly works" because of the partial-agonist label. This is incorrect. Aripiprazole is fully effective for treating psychosis — the partial agonism refers to the molecular interaction at the receptor, not to clinical efficacy. Multiple large clinical trials and meta-analyses have shown aripiprazole to be as effective as other atypical antipsychotics for schizophrenia and bipolar mania.

Abilify has had a long and impactful presence in psychiatric care since its FDA approval in November 2002. Originally developed by Otsuka Pharmaceutical in Japan, aripiprazole was the first third-generation antipsychotic to reach the market and pioneered the partial-agonist approach that influenced subsequent drug development. Its commercial success made it one of the highest-selling medications in the world during the late 2000s and early 2010s before going generic.

Timeline of major milestones

Commercial significance

At its peak around 2013–2014, brand Abilify was the highest-selling medication in the United States, with annual sales exceeding $7 billion. This commercial success funded extensive post-marketing safety research and supported the development of multiple new formulations including long-acting injections.

Generic era

Following patent expiry in 2015, generic aripiprazole became widely available at substantially lower cost. This dramatically expanded access:

• Cost reduction — generic aripiprazole costs 5–15% of brand-name Abilify
• Coverage expansion — many more public health plans and patient assistance programs cover it now
• Global availability — generic versions are produced by manufacturers worldwide
• Long-term affordability — for chronic conditions requiring lifelong treatment

Position in modern treatment guidelines

Schizophrenia was Abilify's original FDA indication and remains its most important use. Aripiprazole is effective for both the positive symptoms (hallucinations, delusions, disorganised thinking) and, to a lesser extent, the negative symptoms (apathy, social withdrawal, blunted emotion) of schizophrenia. It is now considered a first-line treatment in most international clinical guidelines.

Positive vs negative symptoms

Standard schizophrenia dosing

What to expect during treatment

Recovery trajectories on aripiprazole for schizophrenia typically follow this pattern:

• Week 1–2: Sleep improvement, reduction in agitation, beginning improvement in disorganised thinking
• Week 2–4: Hallucinations and delusions begin to fade in intensity or become less distressing
• Week 4–6: Most positive symptoms substantially improved; negative symptoms may begin to improve
• Month 2–6: Stable maintenance achieved; functional recovery (work, social, daily activities) progresses
• Beyond month 6: Long-term maintenance to prevent relapse

Comparison with other antipsychotics for schizophrenia

Treatment-resistant schizophrenia

When aripiprazole or other first-line antipsychotics do not produce adequate response after 2 trials of 4–6 weeks each at optimal dose, clozapine is the recommended next step. Aripiprazole is sometimes used as an adjunct to clozapine to reduce clozapine-induced weight gain or prolactin issues. Long-acting injectable aripiprazole (Maintena) may also be considered when oral adherence is a problem.

Abilify is FDA-approved for three different uses in bipolar I disorder: acute treatment of manic and mixed episodes, maintenance therapy to prevent recurrence, and adjunctive treatment with mood stabilisers like lithium or valproate. It is widely used in modern bipolar treatment because of its rapid action on mania, favourable weight profile compared to other atypicals, and broad effectiveness across illness phases.

Acute manic and mixed episodes

Bipolar I maintenance therapy

After resolution of an acute episode, aripiprazole is approved for maintenance treatment to prevent recurrence:

• Maintenance dose: usually the same dose that worked acutely (10–30 mg daily)
• Duration: at minimum 6–12 months after first episode; often indefinite after recurrent episodes
• Goal: prevent both manic and depressive episodes, maintain functional stability
• Long-acting injectable (Abilify Maintena) approved for bipolar maintenance — useful when adherence is problematic

Adjunctive use with mood stabilisers

Aripiprazole is frequently combined with traditional mood stabilisers:

Pediatric bipolar disorder

What aripiprazole helps less with in bipolar disorder

Aripiprazole's evidence base is strongest for manic and mixed episodes and maintenance after these episodes. It is less consistently effective for:

• Bipolar depression — aripiprazole monotherapy is not approved for bipolar I depression; consider lurasidone, quetiapine, or cariprazine instead
• Rapid cycling — mood stabilisers (lithium, valproate, lamotrigine) are mainstays
• Long-term mood stabilisation without acute episodes — lithium has more evidence here

What to expect during bipolar treatment

• Week 1: Reduced agitation and improved sleep often noticeable
• Week 2–3: Mood and energy beginning to normalise from manic peaks
• Month 1: Substantial symptom resolution in most responders
• Month 2–3: Functional recovery progressing
• Long-term: Continued maintenance to prevent recurrence; periodic reassessment

Abilify was approved by the FDA in 2007 as an adjunctive (add-on) treatment for major depressive disorder in adults who have not responded adequately to a standard antidepressant alone. This represents a distinct use from its psychiatric primary indications: in MDD, aripiprazole is not a standalone treatment but is added to ongoing SSRI or SNRI therapy. About one in three patients with depression do not respond to a single antidepressant trial, making adjunctive options like aripiprazole clinically important.

When aripiprazole is added to an antidepressant

Dosing for MDD adjunctive use

Doses for MDD adjunctive use are typically lower than schizophrenia or bipolar doses. The mechanism involves the 5-HT1A partial agonism and 5-HT2A antagonism rather than primarily dopaminergic effects.

What to expect when aripiprazole is added

• Week 1–2: Some patients notice improvement in energy, motivation, or anxiety
• Week 4–6: Most responders show clear improvement in mood, sleep, and functioning
• Response rates: approximately 25–30% of partial responders to an antidepressant alone will become full responders with aripiprazole added
• Time to assess effectiveness: at least 6–8 weeks at the chosen dose

Which antidepressants combine well with aripiprazole

Side effects to watch for in MDD use

Duration of adjunctive treatment

If aripiprazole helps, it is usually continued for as long as the primary antidepressant is continued. The Adjustment Period:

• Continue at least 6–9 months after full remission of depression
• Then consider gradual taper of aripiprazole while keeping the antidepressant
• If depression returns on antidepressant alone, restart aripiprazole adjunct
• For recurrent depression, indefinite adjunctive treatment may be appropriate

In 2009, the FDA approved Abilify for irritability associated with autism spectrum disorder in children and adolescents ages 6 to 17. This was one of the first medications specifically studied for behavioural symptoms in autistic children and remains an important option when behavioural and developmental interventions alone are insufficient. Aripiprazole does not "treat autism" itself — it addresses specific behavioural symptoms that can interfere with daily function and learning.

What "irritability" means in this context

The clinical concept of irritability in autism includes a specific set of disruptive behaviours that can occur in some autistic children:

• Aggression — hitting, biting, kicking others
• Severe tantrums — intense, prolonged, disproportionate emotional outbursts
• Self-injurious behaviour — head-banging, scratching, biting oneself
• Quickly changing moods — rapid shifts from calm to severe distress
• Property destruction — breaking objects in distress

These behaviours are not core features of autism itself. They are secondary — often arising from distress, sensory overload, communication frustration, or co-occurring conditions. Aripiprazole helps reduce the intensity and frequency of these behaviours, making it easier for children to participate in school, therapy, family life, and learning.

What aripiprazole does NOT do

Standard dosing for pediatric autism irritability

What to expect on aripiprazole for autism irritability

Side effects specific to pediatric autism use

• Weight gain — the most common concern in pediatric use; monitor every visit
• Sedation, somnolence — common at start; usually improves
• Increased appetite
• Drooling — can occur in young children
• Tremor or restlessness (akathisia) — harder to recognise in young children; ask about discomfort
• Fatigue — may affect school participation
• Elevated prolactin — less common than with risperidone but possible

The role of medication in autism care

Aripiprazole is one tool among many in autism care. It should be considered when:

• Irritability is severe enough to interfere with daily life, learning, or safety
• Behavioural interventions and environmental adjustments have been tried
• Co-occurring conditions (sensory issues, sleep problems, gastrointestinal pain) have been addressed
• Family and treatment team agree medication is appropriate

In 2014, the FDA approved Abilify for treatment of Tourette syndrome in children and adolescents ages 6 to 18. Tourette syndrome is a neurodevelopmental disorder characterised by repetitive, involuntary movements (motor tics) and vocalisations (vocal tics). Most children with Tourette do not require medication, but aripiprazole is an option for those whose tics significantly interfere with daily life, school, or self-esteem.

What Tourette syndrome involves

Most children develop tics between ages 5 and 10. Tic severity typically peaks around ages 10–12, then improves through adolescence. Many adults have substantially fewer tics than during childhood. Coprolalia (the involuntary utterance of profanity often portrayed in media) is actually rare in Tourette syndrome, affecting only about 10% of patients.

When medication is considered

For mild Tourette without significant functional impairment, education, classroom accommodations, and watchful waiting are often the best approach. Tics frequently improve naturally as children grow.

Standard dosing for Tourette syndrome

What to expect on aripiprazole for tics

• Week 1–2: Initial reduction in tic frequency or intensity may be noticeable
• Week 4–6: Maximum benefit typically achieved at chosen dose
• Effectiveness: aripiprazole reduces tic severity by approximately 30–50% in most responders
• Complete tic elimination is uncommon — the goal is functional improvement, not zero tics
• Long-term: may be tapered as the child grows and natural improvement occurs

Comparison with other tic-reducing medications

Co-occurring conditions in Tourette

Many children with Tourette also have:

• ADHD — affects about 60% of children with Tourette; may need separate treatment with stimulants or alpha-2 agonists (note: stimulants can worsen tics in some patients)
• OCD — affects 40–50%; SSRI treatment is often needed
• Anxiety disorders — common; therapy is mainstay
• Learning differences — require educational accommodations

This is the master reference for Abilify dosing across all FDA-approved indications and patient populations. Refer to this whenever specific questions arise. Always confirm dosing with your prescriber — this is a summary of standard practice and FDA labelling, not a substitute for personalised psychiatric care.

Oral aripiprazole dosing — adults

Oral aripiprazole dosing — pediatric

Long-acting injectable aripiprazole — Abilify Maintena

Other dose-affecting factors

Starting and adjusting aripiprazole correctly is one of the most important factors in tolerating the medication. The general principle is "start low, go slow" — particularly important because aripiprazole has a long half-life (about 75 hours), so any dose change takes about 2 weeks to reach steady state. Rushing the titration is the most common preventable cause of side effects and treatment discontinuation.

Why titration matters with aripiprazole

• Long half-life means dose changes take 2 weeks to fully express — side effects that look acceptable on day 3 may worsen by day 14
• Akathisia (the signature aripiprazole side effect) is dose-dependent — faster titration causes more akathisia
• Initial activation — first few days can include increased energy, mild anxiety, sleep changes; these often improve with time at the same dose
• Patient confidence and adherence are better with gentle titration than aggressive starts

Standard titration approach for adult schizophrenia or bipolar

Slower titration scenarios

The maintenance dose concept

Once an effective dose is established and the patient is stable, maintenance dose means the steady amount taken daily long-term. Key principles:

• Continue the dose that achieved remission — do not lower "just because the patient feels well"
• Lower doses may reduce efficacy — relapse risk increases substantially
• Higher doses do not usually improve outcomes once optimal response is achieved — they add side effects
• Reassess periodically — every 6–12 months reconsider whether dose can be lowered
• For chronic conditions like schizophrenia, maintenance is typically lifelong at the effective dose

When to reassess and consider adjustment

Stopping or lowering aripiprazole

Once on a stable maintenance dose, changes should always be:

• Discussed with the prescriber first — do not self-adjust
• Gradual — reduce by no more than 25–50% per step
• Spaced out — at least 2–4 weeks between reductions
• Monitored — watch for symptom return
• Reversible — if symptoms return, resume the prior effective dose

Aripiprazole is available in multiple formulations designed to fit different clinical needs, patient preferences, and adherence challenges. The most common forms are standard tablets and the Abilify Maintena long-acting monthly injection, but oral solutions, orally disintegrating tablets, and other long-acting injectables exist as well. Choosing the right formulation matters as much as choosing the right dose.

All available aripiprazole formulations

Standard tablets — the default

Most patients start and continue on standard oral tablets. They are:

• Inexpensive — particularly the generic forms
• Easy to dose — one tablet daily for most patients
• Flexible — can adjust by combining strengths
• Reliable — consistent absorption, well-studied

Long-acting injectables (LAI) — when adherence is a concern

Maintena initiation protocol

Starting Abilify Maintena requires careful coordination:

1. Establish tolerability on oral aripiprazole first (typically 2–4 weeks minimum)
2. First Maintena injection — 400 mg IM in the deltoid or gluteus
3. Overlap period — continue oral aripiprazole at the effective dose for 14 days after first injection (to maintain plasma levels until LAI builds up)
4. Subsequent injections — every 4 weeks (no further oral overlap needed)
5. Dose adjustment if 400 mg not tolerated — reduce to 300 mg monthly

What to do if a Maintena dose is missed

Practical formulation choice considerations

• Generic standard tablets are by far the cheapest option for stable adherent patients
• Oral solution can be substituted in patients who develop swallowing problems mid-treatment
• Long-acting injectables are typically 5–10x more expensive than oral but improve outcomes in adherence-vulnerable populations
• Switching from oral to LAI requires a transition plan with prescriber
• Switching from LAI back to oral takes weeks because of slow injection-site release

One of the simpler aspects of aripiprazole therapy is that food has minimal effect on absorption. You can take Abilify with or without food — whichever fits your daily routine. This simplicity makes it easier to fit aripiprazole into different schedules and lifestyles, and removes one common source of confusion that complicates other psychiatric medications.

The bottom line on food

Pharmacokinetic data on food effects

Timing considerations beyond food

While food does not matter much, timing of dose can affect comfort:

Specific food and drink considerations

If you have stomach upset

Mild nausea is uncommon but can occur with aripiprazole. Strategies:

• Take with a small snack (crackers, banana, toast)
• Drink a full glass of water with each dose
• Try shifting dose to a different time of day
• If persistent vomiting, contact prescriber promptly — do not skip doses

Consistency matters more than timing

Aripiprazole has a distinctive dose-adjustment profile compared to many other medications. Renal impairment does not require dose adjustment — aripiprazole is not primarily kidney-cleared. Hepatic impairment in most cases also does not mandate adjustment. The biggest dose changes come from drug-drug interactions via CYP2D6 and CYP3A4 enzymes, and from genetic variation in CYP2D6 metabolism. Understanding these factors helps prevent both inadequate response and toxicity.

Liver function and aripiprazole

Kidney function and aripiprazole

Aripiprazole is primarily metabolised by the liver (via CYP2D6 and CYP3A4) and only minimally excreted by the kidneys. As a result:

• No dose adjustment needed for any degree of renal impairment
• Safe in dialysis patients (aripiprazole is not removed by dialysis — standard dose appropriate)
• Safe in acute kidney injury from a pharmacokinetic perspective
• This is a significant advantage in elderly patients and those with comorbid conditions affecting kidneys

CYP enzyme interactions — the main source of dose changes

CYP2D6 genetic variation

About 7–10% of white populations and significant proportions of other ethnic groups have genetic variants that make them poor metabolisers of CYP2D6 substrates including aripiprazole. These patients:

• Have plasma aripiprazole levels roughly 60% higher than normal metabolisers at the same dose
• Are more prone to side effects at standard doses
• Should typically start at half the usual starting dose
• May need lower maintenance doses
• Can be identified by CYP2D6 genetic testing (sometimes done in patients with prior medication intolerance)

Less common is the ultra-rapid metaboliser phenotype, where CYP2D6 activity is increased — these patients may need higher doses but rarely require formal adjustment from the start.

Other special population considerations

Abilify (aripiprazole) has a side-effect profile that is generally more favourable than older antipsychotics but still requires careful monitoring. The signature side effect of aripiprazole is akathisia (inner restlessness), which is distinctive and important to recognise. Compared to other atypical antipsychotics, aripiprazole has less weight gain, less sedation, less prolactin elevation, and less risk of metabolic syndrome — making it a preferred long-term choice in many treatment plans.

🔔 Side effect zones (use this as a quick navigation guide)

📌 Most reported everyday side effects (what they feel like)

📋 Symptom-to-action table (fast problem solving)

🌟 What increases side effects (the hidden multipliers)

Rare serious reactions — less than 1 in 1000

• Neuroleptic malignant syndrome (NMS) — very rare; high fever + muscle rigidity + autonomic instability + altered mental state; immediate emergency
• Tardive dyskinesia — involuntary movements (face, tongue, limbs) that may persist after stopping; far less common with aripiprazole than first-gen antipsychotics
• Severe skin reactions (SJS/TEN) — rare; spreading rash, blistering, mucous involvement
• Diabetic ketoacidosis — rare; in patients developing new diabetes
• Seizures — rare; risk slightly elevated in seizure-prone patients
• Severe impulse control disorders — pathological gambling, hypersexuality, binge eating, compulsive shopping (see dedicated section)
• Suicide-related events — antidepressant adjunctive use; monitor especially in young adults at start

Akathisia is the signature side effect of aripiprazole — the most common reason patients consider stopping the medication and a sensation that, when it occurs, can be intensely distressing. The good news is that akathisia is recognisable, manageable, and often reversible with the right approach. Understanding what it is, how to recognise it, and what to do dramatically improves the likelihood of staying on effective treatment.

What akathisia feels like

How common is akathisia on aripiprazole

Why akathisia happens with aripiprazole

The proposed mechanism is the partial agonist activity at D2 dopamine receptors. At certain receptor occupancy levels, aripiprazole produces a kind of mismatch between dopamine activity in different brain regions that manifests as motor restlessness. This is also why akathisia is the most distinctive side effect of aripiprazole compared to other antipsychotics — the unique partial-agonist mechanism creates this specific pattern.

Risk factors for akathisia

• Higher doses — risk increases with dose
• Rapid titration — not allowing 2 weeks between dose increases
• Younger age — adolescents and young adults more affected
• Female sex — somewhat more affected on average
• Concurrent stimulants — methylphenidate, amphetamines, caffeine
• Prior akathisia experience — with any antipsychotic
• CYP2D6 poor metaboliser status (genetic)
• Concurrent CYP2D6 or CYP3A4 inhibitors

When akathisia typically appears

Management of akathisia — first-line strategies

1. Dose reduction — often the most effective approach; reduce by 5–10 mg and wait 2 weeks
2. Slow titration — if dose increases caused it, return to prior dose and titrate slower
3. Reduce or eliminate caffeine — coffee, energy drinks can dramatically worsen akathisia
4. Improve sleep — sleep deprivation worsens akathisia
5. Stress management — meditation, walking, relaxation techniques
6. Address concurrent CYP-inhibiting medications

Management of akathisia — pharmacological treatment

If non-pharmacological measures and dose adjustment do not resolve akathisia, medications can help:

The serious risk: akathisia and suicide

When to switch off aripiprazole due to akathisia

• Akathisia persists despite dose reduction to minimum effective dose
• Akathisia persists despite beta-blocker treatment
• Patient is unable to function or sleep
• Suicidal thoughts emerge with akathisia
• Patient strongly prefers to switch

Alternatives include other atypical antipsychotics with lower akathisia profiles (quetiapine, olanzapine) or first-generation antipsychotics if benefits outweigh other side effects.

One of aripiprazole's main advantages over many other atypical antipsychotics is its relatively favourable metabolic profile. Compared to olanzapine, clozapine, or quetiapine — which can cause substantial weight gain and metabolic syndrome — aripiprazole typically causes modest weight changes. However, "modest" is not "zero". Significant weight gain does occur in some patients, particularly pediatric users, those starting with normal weight, and those on long-term high-dose therapy.

How much weight gain to expect on aripiprazole

About 10–15% of adult patients on aripiprazole gain more than 7% of their baseline body weight — the clinical threshold for "significant" weight change. This is much lower than the 30–50% who gain that much on olanzapine.

Comparison with other atypical antipsychotics

Why weight gain happens on aripiprazole

The mechanisms are not fully understood but involve:

• Histamine H1 blockade — promotes appetite (less than older atypicals)
• 5-HT2C blockade — affects satiety signalling
• Sedation — reduced activity in some patients
• Symptom improvement — patients with active psychosis often eat poorly; recovery includes return to normal eating
• Snacking from medication-related dry mouth or boredom

Other metabolic changes to monitor

Strategies to prevent or minimise weight gain

• Discuss expectations with prescriber at start of treatment
• Weigh weekly for first 3 months — catch trends early
• Dietary changes — reduce sugary drinks, refined carbohydrates, late-night snacks
• Regular exercise — 30 min walking daily helps significantly
• Adequate sleep — poor sleep worsens metabolic changes
• Hydration — water instead of sugary beverages
• Avoid trigger combinations — especially aripiprazole + valproate combination has more weight gain
• Consider metformin — if significant weight gain or insulin resistance develops

When to consider switching due to metabolic concerns

Pediatric patients deserve special attention

Children and adolescents on aripiprazole gain weight more readily than adults. For pediatric patients:

• Monitor weight, height, BMI percentile at every visit
• Monitor fasting glucose and lipids every 6 months
• Family meal planning and physical activity guidance
• Lower threshold for switching if significant metabolic changes occur
• Discuss expectations with family at start

Tardive dyskinesia (TD) is a movement disorder characterised by involuntary repetitive movements, particularly of the face, mouth, tongue, and sometimes limbs and trunk. It is one of the most concerning long-term risks of any antipsychotic medication because the movements can be persistent even after the medication is stopped. The good news is that aripiprazole has a substantially lower risk of TD than first-generation antipsychotics and is also less risky than some other atypicals. The further good news is that newer treatments now exist if TD does develop.

What tardive dyskinesia looks like

Risk on aripiprazole specifically

Cumulative risk over years matters: a patient on aripiprazole for 10 years has roughly 5–10% lifetime risk of developing some TD, compared to 50% or more with first-generation antipsychotics over the same period.

Risk factors for tardive dyskinesia

• Cumulative dose exposure — total amount over years matters most
• Duration of treatment — longer is higher risk
• Older age — particularly age 65+
• Female sex — somewhat higher risk
• Diabetes — independent risk factor
• African or Asian ancestry — slightly higher genetic susceptibility
• History of acute movement disorders on antipsychotics
• Negative symptoms or cognitive impairment in schizophrenia — suggests neurodegenerative vulnerability
• Mood disorders — bipolar patients have slightly higher TD risk than schizophrenia

Detection — the AIMS examination

Self-monitoring tips

Patients can also monitor at home:

• Mirror check — observe face for tongue movements or jaw tics, ideally with eyes closed (TD often worsens then)
• Family/friend observations — they may notice changes you do not
• Photographs over time — comparing facial appearance over months
• Note changes — new tongue movements, lip movements, finger fidgeting
• Report promptly — do not wait for next appointment if changes emerge

What to do if TD develops

New TD treatments: VMAT2 inhibitors

FDA approval of valbenazine (Ingrezza) in 2017 and deutetrabenazine (Austedo) in 2017 has changed the outlook for TD:

• Both reduce TD severity by 30–50% in most patients
• Allow continuation of antipsychotic if needed
• Generally well-tolerated
• Can be combined with antipsychotic switching strategies
• Specialty prescription — often through movement disorder clinics

Prognosis — can TD reverse?

Abilify has relatively few absolute contraindications — it is generally a tolerable medication. However, certain conditions require careful consideration before starting, dose adjustment, or active monitoring. The boxed warning for elderly patients with dementia-related psychosis is the most important single contraindication and reflects increased mortality in that specific population.

🚫 Absolute contraindications (do not use)

🟡 Relative contraindications (use only with caution)

🟢 Conditions requiring caution but not contraindicated

The boxed warning — elderly with dementia

Decision table: should you start Abilify?

What to tell your prescriber before starting

• Complete current medication list including OTC and supplements
• Any neurological or movement disorder history
• Any liver, kidney, or cardiac disease
• History of seizures
• Allergic reactions to any psychiatric medications
• Pregnancy status, breastfeeding, or pregnancy planning
• Alcohol use, recreational substance use
• Family history of psychiatric or movement disorders
• Prior antipsychotic experiences (good and bad)
• Any history of gambling, hypersexuality, or impulsive behaviour

Pregnancy and breastfeeding decisions while on aripiprazole are complex. Untreated severe psychiatric illness in pregnancy carries real risks to both mother and baby, while medication exposure also carries some risks. The most current evidence suggests aripiprazole is relatively safe in pregnancy — but the decision is individualised and should always be made with both psychiatric and obstetric input.

What the pregnancy data shows

FDA pregnancy classification

Under the older FDA pregnancy categorisation, aripiprazole was classified as Category C — animal studies showed effects but no controlled human studies. Modern FDA labelling uses narrative summaries rather than letter categories, but the underlying safety profile has not changed substantially.

Considerations during pregnancy

Decision-making during pregnancy

Comparison with other antipsychotics in pregnancy

Newborn considerations

Babies exposed to aripiprazole in late pregnancy may experience transient symptoms after birth:

• Extrapyramidal symptoms — tremor, increased tone, abnormal movements
• Withdrawal symptoms — jitteriness, feeding difficulty, irritability
• Respiratory issues — rarely
• Usually resolves within hours to days with supportive care
• Delivery hospital should be aware to monitor and respond if symptoms develop

Breastfeeding on aripiprazole

Postpartum considerations

• Postpartum psychiatric illness can be severe; do not discontinue aripiprazole unilaterally after delivery
• Coordinate maternal psychiatric care with infant paediatric follow-up
• Sleep deprivation worsens psychiatric symptoms; family support critical
• Consider increasing monitoring frequency in first weeks postpartum
• Postpartum psychosis is a psychiatric emergency requiring urgent treatment

Aripiprazole is one of the most extensively studied antipsychotics in children and adolescents. FDA approvals for pediatric use span four indications across ages 6 to 17: irritability in autism (6–17), Tourette syndrome (6–18), schizophrenia in adolescents (13–17), and bipolar I disorder in children (10–17). This breadth of approved pediatric uses reflects the substantial clinical research base and represents one of aripiprazole's distinctive strengths in pediatric psychiatry.

Approved pediatric indications — comprehensive summary

Pediatric-specific titration

Pediatric pharmacokinetics

Aripiprazole's behaviour in children is similar to adults but with some differences:

• Half-life — about 75 hours, similar to adults
• Bioavailability — similar to adults
• CYP2D6 polymorphism — same considerations as adults; pediatric CYP2D6 variants particularly important
• Weight-based dosing — particularly important for Tourette and young children
• Once-daily dosing works for children, supporting adherence

Side effects that matter more in pediatric patients

Pediatric monitoring requirements

Special situations in pediatric use

• Combined ADHD treatment — if child has both Tourette and ADHD, stimulants can worsen tics; aripiprazole + alpha-2 agonists may be preferred
• Combined autism + irritability + ADHD — complex; psychostimulants and aripiprazole sometimes combined cautiously
• Bipolar in young children — controversial diagnosis; second opinions often valuable
• Adolescent first-episode psychosis — aripiprazole is a reasonable first-line choice

Pediatric long-term considerations

Family education and support

Pediatric aripiprazole treatment works best when families are informed and involved:

• Discuss realistic expectations about what the medication can and cannot do
• Establish open communication about side effects
• Encourage age-appropriate involvement of child in their own care
• Address concerns about long-term effects honestly
• Connect families with support resources for the underlying condition
• Plan for school communication and accommodations

The single most important safety topic for aripiprazole in older patients is the FDA boxed warning for elderly patients with dementia-related psychosis. Issued in 2006 and applying to all atypical antipsychotics, this warning reflects clinical trial data showing significantly increased mortality when antipsychotics are used to manage behavioural symptoms of dementia. Understanding this warning, how to apply it, and how to manage non-dementia psychiatric conditions in elderly patients is essential.

The boxed warning — what it says

What "dementia-related psychosis" means

This term refers to behavioural and psychological symptoms of dementia (BPSD) — not to elderly patients with primary psychiatric disorders. Examples include:

• Agitation and aggression in advanced dementia
• Hallucinations or delusions secondary to Alzheimer's disease or other dementias
• Behavioural disturbance in late-stage dementia
• Wandering or repetitive vocalisations

The warning does NOT apply to:

• Elderly patients with primary schizophrenia (lifelong illness)
• Elderly patients with primary bipolar disorder
• Elderly patients with severe depression requiring adjunctive aripiprazole
• Elderly patients with primary Tourette syndrome or other approved indications

Standard approach for elderly with non-dementia psychiatric illness

Approach for dementia-related agitation (when behavioural measures fail)

If dementia-related psychosis or severe agitation is unmanageable with non-pharmacological approaches, antipsychotic use is sometimes considered despite the warning. In such cases:

Specific risks elevated in elderly patients

Monitoring schedule for elderly aripiprazole patients

Most clinically important aripiprazole drug interactions involve the liver enzymes CYP2D6 and CYP3A4, which together metabolise aripiprazole into its main active metabolite (dehydroaripiprazole) and eventually clear it from the body. Drugs that inhibit either enzyme can dramatically raise aripiprazole plasma levels; drugs that induce either can dramatically lower them. Knowing the common offenders and how to adjust the dose accordingly prevents both toxicity and treatment failure.

How aripiprazole is metabolised

Strong CYP2D6 inhibitors — common offenders

Dose adjustment: when starting one of these alongside aripiprazole, reduce aripiprazole by 50%. Conversely, when stopping a CYP2D6 inhibitor, return to full aripiprazole dose.

Strong CYP3A4 inhibitors — common offenders

Strong CYP enzyme inducers — lower aripiprazole levels

Dose adjustment: when adding a strong inducer, double the aripiprazole dose over time and watch for symptom emergence. When stopping an inducer, return aripiprazole to original dose gradually.

The "double whammy" — combined inhibitors

Common medications that DO NOT significantly interact

• Most SSRIs other than paroxetine and fluoxetine — sertraline, escitalopram, citalopram are safe
• SNRIs — venlafaxine, duloxetine usually fine
• Most antihypertensives — ACE inhibitors, beta-blockers, most CCBs safe
• Statins — atorvastatin, rosuvastatin, etc.
• Common antibiotics other than macrolides — amoxicillin, doxycycline safe
• NSAIDs — ibuprofen, naproxen, etc.
• Most psychiatric medications — lithium, valproate, lamotrigine, most other antipsychotics
• OTC medications — most acetaminophen, antihistamines, etc.

Aripiprazole is frequently combined with other psychiatric medications — particularly antidepressants, mood stabilisers, and anti-anxiety drugs. Most combinations are safe and clinically useful, but specific pairings deserve special attention either because of pharmacokinetic interactions or because of pharmacodynamic (additive effect) considerations. Understanding which combinations work well and which require caution is essential for patients on complex regimens.

Aripiprazole + antidepressants

Aripiprazole + mood stabilisers

Aripiprazole + other antipsychotics

Aripiprazole + benzodiazepines

• Lorazepam, clonazepam, diazepam — safe combination from a drug-interaction standpoint
• Short-term use for severe agitation or akathisia is appropriate
• Long-term combined use raises sedation, fall risk, and dependence concerns
• Withdrawal coordination — if both are eventually tapered, do not stop both at once

Aripiprazole + stimulants (for ADHD comorbidity)

The interaction between aripiprazole and lifestyle substances — alcohol, caffeine, nicotine, cannabis, and recreational drugs — matters more than for many medications because aripiprazole affects multiple brain systems involved in mood, alertness, and judgement. Most combinations are manageable, but some have specific concerns worth understanding. Honest discussion with your prescriber about your substance use is essential for safe care.

Aripiprazole and alcohol

Alcohol use guidance during aripiprazole therapy

Caffeine and aripiprazole

Nicotine, smoking, and aripiprazole

• Smoking induces CYP1A2 — but aripiprazole is not metabolised by CYP1A2, so smoking does not directly affect aripiprazole levels
• No formal dose adjustment needed for smokers or non-smokers
• Smoking cessation — does not require aripiprazole dose change
• Smoking common in schizophrenia patients — mental-health counselling on smoking cessation is encouraged but not urgent for aripiprazole interaction

Cannabis and aripiprazole

Other recreational substances

Why honest disclosure matters

Specific guidance for common scenarios

• "I drink wine at dinner sometimes": Usually fine; watch sedation; do not drive after
• "I drink coffee in the morning": Fine if no akathisia; reduce if restless
• "I smoke cannabis occasionally": Discuss with prescriber; particularly important for primary psychotic disorders
• "I use methamphetamine periodically": Major concern; integrated substance and psychiatric treatment needed
• "I am sober but want to drink at a wedding": Generally OK in moderation; discuss with sponsor and prescriber

While aripiprazole has a more favourable metabolic profile than many other atypical antipsychotics, diabetes and hyperglycemia remain real concerns for long-term users. The FDA requires a warning about hyperglycemia and diabetes mellitus on all atypical antipsychotics. Vigilant monitoring and early intervention prevent most problems — but the risk is not zero, particularly in patients with other risk factors.

Why atypical antipsychotics affect glucose

The mechanisms are complex and not fully understood, but involve:

• Direct effects on insulin sensitivity — some atypicals reduce insulin response
• Weight gain — the biggest contributor; abdominal fat especially affects insulin resistance
• Effects on appetite regulation — increased food intake
• Sedation-related decreased activity — less exercise
• Lipid profile changes — triglycerides and cholesterol can rise

Relative risk by antipsychotic

Standard metabolic monitoring on aripiprazole

Warning signs of hyperglycemia

Risk factors that increase diabetes risk on aripiprazole

• Pre-existing prediabetes or impaired fasting glucose
• Family history of type 2 diabetes
• Higher baseline BMI (overweight or obese)
• Sedentary lifestyle
• Age 45+
• South Asian, African American, Hispanic ethnicity (higher background diabetes risk)
• Polycystic ovary syndrome in women
• History of gestational diabetes
• Hypertension or dyslipidemia

Diabetic ketoacidosis — rare but serious

Management strategies if hyperglycemia develops

1. Confirm diagnosis — fasting glucose, HbA1c
2. Address modifiable factors — weight, exercise, diet
3. Consider whether to continue aripiprazole — weighing psychiatric needs vs metabolic concerns
4. If continuing: add antidiabetic medication (metformin first-line); intensive lifestyle support
5. If switching: consider lurasidone or ziprasidone (lower metabolic profile)
6. Endocrinology consultation for established diabetes

Aripiprazole + metformin for prevention

For pediatric and elderly patients

• Children and adolescents: closer monitoring needed; growing endocrine system; family education about diet and activity
• Elderly: often have undetected baseline glucose issues; check thoroughly before start
• Pregnant women: gestational diabetes screening more vigilant; aripiprazole continued if benefits justify

One of the most distinctive and concerning side effects of aripiprazole — relatively unique among antipsychotics — is the potential to cause impulse control disorders: pathological gambling, hypersexual behaviour, binge eating, and compulsive shopping. The FDA issued a warning in 2016 after multiple post-marketing reports. While these are rare, they can be devastating when they occur. Awareness is the key to early recognition and prompt intervention.

What impulse control disorders look like

How common is this?

Exact incidence is difficult to determine because impulse control disorders may be underreported (due to shame, lack of awareness of the medication connection, or denial). Based on available reports:

• Pathological gambling: reported in roughly 1–3% of long-term aripiprazole users
• Hypersexual behaviour: less precisely quantified; reported with some frequency
• Binge eating: probably more common than reported due to shame
• Total impulse control disorders: perhaps 5–10% of users have some degree of these urges

Why does aripiprazole cause this?

The mechanism is hypothesised to involve aripiprazole's dopamine partial agonism. At certain levels of receptor occupancy, the drug may activate dopamine pathways involved in reward and impulse control rather than blocking them. This is consistent with similar reports from other dopamine partial agonists (cariprazine, brexpiprazole) and dopamine agonists used in Parkinson's disease (pramipexole, ropinirole).

Risk factors for impulse control disorders

• Prior history of impulse control problems or addiction
• Family history of addiction or gambling
• Younger age
• Bipolar disorder diagnosis (impulsivity already part of illness)
• Substance use history
• Higher aripiprazole dose
• Specific psychiatric comorbidities (ADHD, antisocial traits)

Recognition and self-monitoring

What to do if impulse control disorders develop

Management options

• Dose reduction — often resolves the urges; sometimes maintains efficacy
• Switching to alternative antipsychotic — without partial agonism (olanzapine, quetiapine, risperidone)
• Switching to other class — lurasidone, ziprasidone if metabolic concerns also relevant
• Behavioural therapy — cognitive behavioural therapy for compulsive behaviours
• Support groups — Gamblers Anonymous, sex addiction support groups
• Financial recovery planning — if significant financial damage
• Relationship counselling — if relationship effects

The good news

For families and partners

If you notice changes in a loved one taking aripiprazole:

• New or increased gambling behaviour
• Unexplained financial problems
• Changes in sexual behaviour patterns
• New binge eating episodes
• Excessive online purchases or browsing
• Lying about activities or finances

Discuss the observation supportively. Encourage them to inform their prescriber. The patient may not connect the behaviour to the medication.

One of the less-discussed but clinically important effects of antipsychotic medications including aripiprazole is impairment of temperature regulation. Patients on aripiprazole can develop hypothermia (abnormally low body temperature) in cold environments or hyperthermia (overheating) in hot environments more readily than people not on these medications. Awareness and simple precautions prevent most problems.

Why aripiprazole affects temperature

Temperature regulation involves the hypothalamus, which uses several neurotransmitters including dopamine and serotonin. Aripiprazole's modulation of these systems can subtly impair the body's ability to:

• Recognise cold — reduced subjective awareness of dangerous chilling
• Generate heat — reduced shivering response; reduced vasoconstriction
• Conserve heat — effects on metabolism
• Recognise heat — reduced subjective awareness of dangerous overheating
• Dissipate heat — reduced sweating in some cases

Hypothermia risk — the main concern

Hyperthermia risk — the heat counterpart

Risk factors

• Older age — reduced temperature regulation already
• Higher aripiprazole dose — modest effect
• Concurrent anticholinergic medications — reduce sweating further
• Alcohol use — impairs vasoconstriction and judgement
• Dehydration — reduces heat dissipation
• Limited self-care capacity — severe psychiatric illness, dementia
• Homelessness — environmental exposure
• Outdoor occupations or activities in extreme weather

Cold weather precautions for aripiprazole users

Hot weather precautions

Recognising hypothermia in someone else

Practical winter strategies for patients

• Set heating thermostat with a buffer (warmer than feels needed)
• Sleep with extra blankets
• Carry hand warmers in pocket during outdoor time
• Schedule wellness check-ins with family during cold snaps
• Have backup heating if power outages possible
• Inform family or carers about the medication's temperature regulation effect
• Avoid solo outdoor activity in extreme cold

Aripiprazole's long half-life of approximately 75 hours makes it forgiving of occasional missed doses. Unlike medications that require precise daily timing, missing one aripiprazole dose rarely causes immediate problems. Still, consistency matters for steady-state plasma levels and symptom control. Knowing what to do when a dose is missed prevents both unnecessary worry and incorrect responses.

Quick decision rule

Note: aripiprazole's tolerance for late doses is much higher than for many medications because of the long half-life. A single missed dose typically affects plasma levels by less than 15%.

Missed dose by treatment type

Why doubling is unnecessary and harmful

Doubling the next aripiprazole dose:

• Does not "make up" for the missed dose — plasma levels with one normal dose recover quickly
• Substantially increases akathisia risk — rapid plasma elevation triggers restlessness
• Increases sedation for that day
• Can cause anxiety or panic if particularly sensitive
• Provides no additional symptom control — the receptors are already saturated at standard doses

Multiple missed doses — longer interruptions

When to call your prescriber

If you run out of medication

Contact your pharmacy or prescriber immediately:

• Most prescriptions can be refilled quickly with insurance verification
• Emergency supply (a few days) usually available through pharmacy
• Tell pharmacist you are on aripiprazole and ran out — many can arrange same-day refill
• If unable to access medication: do not improvise — contact prescriber for guidance
• Patient assistance programs available for unaffordable refills

Strategies to prevent missed doses

Most aripiprazole users complete their treatment without major problems. The patients who experience preventable difficulties usually make one of a small set of avoidable mistakes. Knowing what to avoid is as important as knowing what to do — particularly because some mistakes have lasting consequences (impulse control disorders, severe akathisia, mood destabilisation).

The top mistakes to avoid

Why each matters

1. Stopping abruptly without prescriber guidance

Abrupt discontinuation after weeks/months of treatment can cause: rebound anxiety, rapid return of psychiatric symptoms (sometimes worse than baseline), and rarely withdrawal-like effects. Gradual tapering over weeks is the only safe approach for stopping.

2. Self-adjusting dose

"Taking less because I feel better" or "taking more for a bad day" disrupts steady-state plasma levels. Side effects worsen, symptoms recur, and the long half-life makes inconsistency particularly problematic. Always discuss dose changes with prescriber first.

3. Dementia-related use without informed consent

The boxed warning for increased mortality in elderly dementia patients is real. If aripiprazole is being considered for dementia-related agitation, family and patient must understand the risk-benefit trade-off and choose accordingly. Non-pharmacological approaches first; medication only when alternatives have failed.

4. Ignoring akathisia

Severe akathisia is associated with treatment discontinuation, distress, and rarely suicidal thoughts. It is treatable — dose reduction, beta-blockers, or medication switch. Suffering through severe akathisia silently is never appropriate. Report restlessness promptly.

5. Ignoring impulse control issues

New or worsening gambling, hypersexuality, binge eating, or compulsive shopping are medication side effects, not personal weakness. Reporting them is essential because they usually resolve when the medication is reduced or changed. Hiding them allows financial, relationship, and legal damage to accumulate.

6. Heavy alcohol use

Beyond direct interaction concerns, alcohol worsens depression, anxiety, bipolar instability, and undermines treatment goals. Heavy drinking is a serious treatment adherence and outcome concern. Discuss substance use openly with your prescriber.

7. CYP-affecting medication combinations

Adding strong CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion) or CYP3A4 inhibitors (clarithromycin, ketoconazole) without dose adjustment can effectively double your aripiprazole plasma level, causing significant side effects. Always tell pharmacist about new medications.

8. Sharing or using someone else's prescription

Wrong dose for the wrong person, no medical evaluation, no side-effect monitoring, illegal in most jurisdictions. Aripiprazole is a powerful medication requiring individualised prescription. Never share.

9. Skipping metabolic monitoring

Glucose and lipid changes can be silent until significant problems develop. Skipping monitoring means missing early-stage diabetes or dyslipidemia that would be easy to address with timely intervention. Annual minimum; more frequent for risk factors.

10. Continuing without reassessment

Long-term psychiatric medication is appropriate for chronic conditions, but every 6–12 months ask: is this still needed? At what dose? With what monitoring? Periodic reassessment prevents unnecessary lifelong exposure.

Things commonly worried about — but actually fine

Discontinuing aripiprazole is sometimes appropriate — when symptoms have resolved, when side effects are intolerable, when an alternative is preferable, or when life circumstances change (pregnancy planning, etc.). The key principle is that aripiprazole should almost never be stopped abruptly after sustained use. Gradual tapering over weeks to months, under prescriber guidance, prevents withdrawal-related and rebound symptoms.

When stopping is considered

Standard taper protocol

Why slow tapering matters

• Long half-life misleading — even though it takes 2 weeks to fully clear, symptom-control receptors adjust on their own timescale
• Withdrawal-related symptoms are uncommon but possible (insomnia, nausea, headache, increased anxiety)
• Rebound psychosis — severe symptoms can return rapidly with abrupt stopping
• Cholinergic rebound — transient gastrointestinal upset, vivid dreams
• Reduces psychological adjustment burden — one step at a time

Discontinuation symptoms to expect

Switching to a different antipsychotic

When switching aripiprazole to another antipsychotic (rather than discontinuing entirely):

• Cross-titration is preferred — gradually reduce one while introducing the other
• Direct switch at therapeutic dose is also possible for similar-class medications
• Maintain effective dose of new medication while aripiprazole is reduced
• Coordinate with prescriber — do not improvise switches
• Monitor for both old-medication withdrawal and new-medication side effects during transition

If you must stop suddenly

Long-term planning for discontinuation

Proper storage preserves aripiprazole's potency over its labelled shelf life. The various formulations — tablets, oral solution, orally disintegrating tablets, and injectables — have somewhat different storage requirements. Understanding how to store each, how to travel with the medication, and when to replace deteriorated supplies prevents both clinical problems and unnecessary expense.

Storage by formulation

Temperature storage details for tablets

Humidity and environmental factors

• Bathrooms — surprisingly bad storage location due to humidity from showers; avoid
• Original packaging — designed to protect against moisture and light; keep tablets in blister until use
• Direct sunlight — UV slowly affects tablets; keep in opaque packaging
• Kitchen near stove — periodic heat exposure shortens shelf life
• Pill organisers — convenient for daily-use supplies but not for long-term storage

Oral solution-specific storage

Long-acting injectable storage (Abilify Maintena)

If you receive Maintena at home (rather than in clinic):

• Refrigerate at 2–8°C until ready to use
• Do not freeze — freezing damages the formulation
• Allow to reach room temperature before administration (typically 30 minutes)
• Use within manufacturer's labeled period after removal from refrigerator
• Do not use if cloudy, discoloured, or contains particles after shaking

Travel with aripiprazole

Country considerations for HIV medications

Aripiprazole is a globally available medication. However:

• Most developed countries: widely available; refills possible if you have prescription
• Less-developed countries: may require advance arrangement or sufficient supply
• Some countries restrict psychiatric medications for foreign travellers — check before travel
• Always carry sufficient supply rather than relying on destination availability

Signs your medication may have deteriorated

• Tablets stuck together or appearing damp
• Tablet colour change or surface mottling
• Unusual smell — chemical, vinegar, or other off odour
• Oral solution discolouration or particles after shaking
• Past expiry date
• Packaging punctured or torn before use

Disposal of expired or unused medication